Rituximab in immunologic glomerular diseases
Abbreviated Journal Title
rituximab; glomerular diseases; transplant; rejection; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IDIOPATHIC MEMBRANOUS NEPHROPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTIBODY-ASSOCIATED VASCULITIS; DEPENDENT NEPHROTIC SYNDROME; PROLIFERATIVE LUPUS NEPHRITIS; CHRONIC; LYMPHOCYTIC-LEUKEMIA; ANCA-ASSOCIATED VASCULITIS; B-CELL DEPLETION; RENAL-TRANSPLANTATION; Medicine, Research & Experimental
Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.
"Rituximab in immunologic glomerular diseases" (2013). Faculty Bibliography 2010s. 2601.